Metagenomi Therapeutics (MGX) Current Assets (2023 - 2026)

Metagenomi Therapeutics (MGX) has 4 years of Current Assets data on file, last reported at $144.6 million in Q1 2026.

• Current Assets for Q1 2026 came in at $144.6 million, down 38.01% year-over-year; the trailing twelve-month figure through Mar 2026 was $144.6 million (down 38.01% YoY), and the FY2025 annual result was $165.5 million, down 35.83% from the prior year.
• Current Assets eased to $144.6 million in Q1 2026 per MGX's latest filing, from $165.5 million in the prior quarter.
• Over five years, Current Assets peaked at $335.6 million in Q1 2024 and troughed at $144.6 million in Q1 2026.
• A 4-year average of $240.7 million and a median of $245.6 million in 2024 frame the typical range for Current Assets.
• The sharpest annual moves came in 2024 and 2026: Current Assets fell 7.3% in 2024, then slumped 38.01% in 2026.
• A 4-year view of Current Assets shows it stood at $278.3 million in 2023, then fell by 7.3% to $258.0 million in 2024, then plunged by 35.83% to $165.5 million in 2025, then decreased by 12.67% to $144.6 million in 2026.
• Business Quant data shows MGX's Current Assets at $144.6 million in Q1 2026, $165.5 million in Q4 2025, and $189.8 million in Q3 2025.